BinDawood Holding Co. announces its Interim Financial results for the Period Ending on 2025-06-30 ( Six Months )
| Element List | Current Quarter | Similar quarter for previous year | %Change | Previous Quarter | % Change |
|---|---|---|---|---|---|
| Sales/Revenue | 1,474,313,373 | 1,417,839,299 | 3.983 | 1,674,385,176 | -11.948 |
| Gross Profit (Loss) | 533,285,039 | 480,428,766 | 11.001 | 528,700,362 | 0.867 |
| Operational Profit (Loss) | 80,423,284 | 101,688,196 | -20.911 | 92,784,906 | -13.322 |
| Net profit (Loss) | 50,483,783 | 75,043,712 | -32.727 | 65,716,775 | -23.179 |
| Total Comprehensive Income | 61,255,966 | 74,162,058 | -17.402 | 70,804,272 | -13.485 |
| All figures are in (Actual) Saudi Arabia, Riyals | |||||
| Element List | Current Period | Similar period for previous year | %Change |
|---|---|---|---|
| Sales/Revenue | 3,148,698,549 | 2,890,763,020 | 8.922 |
| Gross Profit (Loss) | 1,061,985,401 | 931,468,265 | 14.011 |
| Operational Profit (Loss) | 173,208,190 | 185,081,204 | -6.415 |
| Net profit (Loss) | 116,200,558 | 135,590,364 | -14.3 |
| Total Comprehensive Income | 132,060,238 | 131,024,537 | 0.79 |
| Total Shareholders Equity (after Deducting Minority Equity) | 1,493,381,119 | 1,471,273,097 | 1.502 |
| Profit (Loss) per Share | 0.1 | 0.12 | |
| All figures are in (Actual) Saudi Arabia, Riyals | |||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Actual) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the same quarter of the last year is | BinDawood Holding Company’s (also referred to as the Company or BDH) Sales Growth – Q2 2025:
• Total revenue reached SAR 1,474.3 million • This exhibits 4.0% increase from Q2 2024 (SAR 1,417.8 million)
Key Reasons for Growth: • Retail Pharma(comprised of Zahrat Al Rawdah Pharmacies LLC): Distinctive performance following the Q1 2025 acquisition, supported by: - Expansion through standalone outlets; and - Successful integration of pharmacy stores within existing BinDawood and Danube stores. • Distribution Business: Positive impact from the Q3 2024 acquisition, contributing to overall revenue growth. • Tech Segment(comprised of IACO and Ykone): Achieved modest growth, driven by: - Improving Ykone’s performance in the Middle East and India. |
| The reason of the increase (decrease) in the net profit during the current quarter compared to the same quarter of the last year is | Gross Profit surged to SAR 533.3 million, driven by increased revenue and a margin improvement to 36.2%, achieved in a challenging market through, the following key drivers:
• Better supplier terms in Retail grocery; and • Margin expansion from high-margin Retail Pharma and Distribution Businesses.
Total Operating Expenses: Increased in absolute terms in Q2 2025 to SAR 453.9 million vs. Q2 2024 SAR 381.5 million which are related mainly to the following key reasons: • Additional costs from the retail pharmacy & distribution business, which were not included in Q2 2024; and • Full-period impact of store operating costs which are relevant to: - stores opened last year; and - New stores launched in 2025
Net Profit: Declined to SAR 50.5 million in Q2 2025 vs. SAR 75 million in Q2 2024, due to the following key drivers: • Higher operating expenses as explained above; • Lower finance income; and • Increased finance costs from the Retail Pharma acquisition. |
| The reason of the increase (decrease) in the sales/ revenues during the current quarter compared to the previous one is | Total revenue reached to SAR 1,474.3 million. This exhibits 11.9% decline from Q1 2025 (SAR 1,674.4 million) Key Reasons for Revenue Decline
• Decline in seasonal sales; • Decline in consumer spending; • However, the tech segment (Ykone) continued to perform well; and • The newly acquired Retail Pharma business showed strong growth, especially due to successful integration of pharmacy stores inside key BinDawood and Danube stores. |
| The reason of the increase (decrease) in the net profit (loss) during the current quarter compared to the previous one is | Gross profit increased slightly by 0.9% to SAR 533.3 million from SAR 528.7 million. However, the gross margin improved to 36.2%, supported by:
• Margin contribution from high-margin Retail Pharma and Distribution businesses; • Better supplier terms in the core grocery segment; and • Effective cost control across operations.
Total Operating Expenses: Increased in absolute terms in Q2 2025 SAR 453.9 million vs Q1 2025 SAR 438.5 million, due to the following key reasons: • Higher expenses due to the full-quarter impact of Retail Pharma operations (consolidated since February 2025); • Additional costs from opening new standalone Retail Pharma stores and integrating pharmacy sections within existing Danube and BinDawood stores during Q2 2025; and • Increased operating expenses from new store openings in the Retail Grocery segment.
Net Profit: Declined to SAR 50.5 million in Q2 2025 vs. SAR 65.7 million in Q1 2025.
Key Drivers: • Higher operating expenses as explained above; • Lower finance income; and • Increased finance costs from the Retail Pharma acquisition. |
| The reason of the increase (decrease) in the sales/ revenues during the current period compared to the same period of the last year is | The Company’s Sales Growth – H1 2025
• Total revenue reached to SAR 3,148.7 million • This exhibits 8.9% increase from H1 2024 (SAR 2,890.8 million)
Key Reasons for Growth: • Retail Pharma: Strong contributor post Q1 2025 acquisition; supported by store expansion and integration within BinDawood and Danube stores. • Distribution Business: Positive impact from H2 2024 acquisition; successful integration of new products into BDH’s network. • Tech Segment: Significant growth; driven by IACO’s online sales and Ykone’s growth in the Middle East, Europe, and India. |
| The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is | Gross profit rose to SAR 1,062.0 million, marking a 14% year-on-year increase. This was driven by higher revenue and an improved gross margin of 33.7%, up from 32.2% in the same period last year, despite a challenging market environment.
Key Drivers: • Growth in overall revenue; • Improved supplier terms in the core grocery segment; and • Stronger margins from Retail Pharma and Distribution businesses.
Total Operating Expenses: Increased in absolute terms in H1 2025 to SAR 892.4 million from SAR 751 million in H1 2024.
Key Reason: • Additional costs from the Retail Pharma and Distribution businesses, which were not included in H1 2024. • Full-period impact of store operating costs for: - BinDawood and Danube stores opened during 2024; and - New BinDawood, Danube and Retail Pharma stores opened in H1 2025 • Higher expenses from integrating pharmacy sections inside key BinDawood and Danube stores. • Increased staffing, utilities and logistics costs associated with new and expanded store operations.
Net Profit: Declined to SAR 116.2 million in H1 2025 vs. SAR 135.6 million in H1 2024.
Key Drivers: • Higher operating expenses as explained above; • Lower finance income; and • Increased finance costs from the Retail Pharma acquisition. |
| Statement of the type of external auditor's report | Unmodified conclusion |
| Comment mentioned in the external auditor’s report, mentioned in any of the following paragraphs (other matter, conservation, notice, disclaimer of opinion, or adverse opinion) | None |
| Reclassification of Comparison Items | No comparative figures for the previous period have been reclassified. |
| Additional Information | Changes in the Statement of Financial Position as at 30th June 2025 (for the six-month period) were as follows:
1. Non-current assets increased by 11.9% resulting from an increase in property and equipment, goodwill and right-of-use assets.
2. Current assets increased by 7.5% mainly due to increase in inventories and trade & other receivables.
3. Current liabilities increased by 14.2% resulting mainly from increase in current portion of bank borrowings and accounts payable.
4. Non-current liabilities increased by 13.4% in H1 2025 mainly because of increase in lease liabilities and long term loan.
5. Total equity increased by 1.3% driven by an increase in retained earnings (net profit for the period) and foreign exchange reserve. |
| Attached Documents |  |
Comments